Headquartered in Mumbai, Glenmark is a research led API & Generic formulations company, with a market presence across 80 countries.

The company's business segment portfolio broadly comprises both formulation and bulk drug sales.

The company follows a branded generic model in markets across Asia, Africa, CIS countries, Russia and Latin America. In contrast, in the highly regulated markets of USA and Europe, it has adopted a business model of registering and marketing generic drugs.

Alongside, Glenmark has also invested and built a novel pipeline of breakthrough NCE through innovation. Glenmark floated its IPO in 1999 and with the capital raised, set up a state-of-the-art research and development centre in Navi Mumbai (Maharashtra) for drug discovery research. Glenmark has built a visible and growing branded generic formulation presence across all its markets.